Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi

The proteasome inhibitor bortezomib is associated with the development of peripheral neuropathy in patients, but the mechanism by which bortezomib can induce peripheral neuropathy is not fully understood. One study suggested that off-target inhibition of proteases other than the proteasome, particul...

Descripción completa

Detalles Bibliográficos
Autores principales: Csizmadia, Vilmos, Hales, Paul, Tsu, Christopher, Ma, Jingya, Chen, Jiejin, Shah, Pooja, Fleming, Paul, Senn, Joseph J., Kadambi, Vivek J., Dick, Larry, Wolenski, Francis S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2016
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062231/
https://www.ncbi.nlm.nih.gov/pubmed/30090462
http://dx.doi.org/10.1039/c6tx00220j

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062231/
https://www.ncbi.nlm.nih.gov/pubmed/30090462
http://dx.doi.org/10.1039/c6tx00220j

Ejemplares similares